CPP Partnership with Dynavax - 6/21/2018
CPP is pleased to announce a new partnership with Dynavax, the manufacturer of the newly approved adult hepatitis-B vaccine Heplisav-B® administered as a 2-dose series. (April 2018 MMWR publication of the ACIP recommendation)
Members of CPP who opt-into the Dynavax contract can access discounted pricing on doses of Heplisav-B® purchased through an authorized distributor. For a complete list of authorized distributors, see attached list or call 1-84-HEPLISAV (1-844-375-4728).
Members who are interested in participating in the CPP/Dynavax contract should contact the CPP office at 614-722-2145 or email@example.com to obtain an opt-in form.
If you have any questions, please don't hesitate to contact us!
Merck Vaccines Supply Interruptions - 7/10/2017
Merck has announced supply interruptions that have impacted availability of several of their vaccines:
•Adult formulation of Vaqta, a hepatitis A vaccine – anticipated return: 2019
•Adult formulation of RecombivaxHB, a hepatitis B vaccine – anticipated return: 2019
•Pediatric formulation of RecombivaxHB, a hepatitis B vaccine – anticipated return: end of 2018
Please note that these interruptions do not impact the supply of the pediatric formulation of Vaqta at this time.
During product shortages, CPP does not enforce program purchase guidelines for the affected vaccines. To stay up to date on product availability, refer to the Merck Vaccines Supply Status website.